CAMBRIDGE, Mass.--Millen nium Pharmaceuticals here has announced two major scientific appointments. Michael Pavia will become the company's chief technology development officer, while Kazumi Shiosaki will be senior director of drug discovery.
Pavia was formerly vice-president of Cambridge Research with the Sphinx Pharmaceuticals division of Eli Lilly. He has a background of over 15 years in pharmaceutical research and discovery, including stints with Genesis Pharmaceuticals and Parke-Davis. In his new position he will head the organization dedicated to Millennium's technology development efforts in such areas as informatics, proteomics, process technologies, systems, transcriptional profiling, technology transfer, and technology acquisition. The company said his responsibilities will include "advancing the development and implementation of Millennium's integrated platform of genomic technologies for broad application in the life sciences arena."
Meanwhile, Shiosaki will lead Millennium's drug discovery group, taking responsibility for such areas as assay development, screening, drug source, and chemistry. With over 13 years of experience in pharmaceutical research and development, she most recently worked at Abbott Laboratories, serving as senior project leader and associate fellow of the Volwiler Society, Antiviral Research. In her new position Shiosaki will direct Millennium's efforts in drug discovery, high-throughput screening, and lead optimization.